J.P. Morgan analyst Casey Woodring maintained a Hold rating on Charles River Labs (CRL – Research Report) yesterday and set a price target of ...
As promised, the restructuring initiatives taking place at Charles River Labs (NYSE: CRL) have resulted in a reduced ...
Q4 2024 Earnings Call Transcript February 19, 2025 Charles River Laboratories International, Inc. beats earnings expectations ...
Baird lowered the firm’s price target on Charles River (CRL) to $173 from $177 and keeps a Neutral rating on the shares. The firm The firm ...
Charles River's Q4 revenue topped estimates despite a 1.1% decline. The company forecasts a revenue drop in 2025, with biotech demand expected to stabilize.
2d
Zacks.com on MSNCRL Stock Up on Q4 Earnings and Revenue Beat, Margins FallCharles River Laboratories International, Inc. CRL reported fourth-quarter 2024 adjusted earnings per share (EPS) of $2.66, ...
Charles River Laboratories, the largest corporate recipient of NIH funding in Mass., is not overly concerned with the ...
Charles River Laboratories International Inc. (CRL) on Wednesday reported a loss of $215.7 million in its fourth quarter. The ...
New York State Teachers Retirement System decreased its holdings in shares of Charles River Laboratories International, Inc. ...
Louisiana State Employees Retirement System cut its position in shares of Charles River Laboratories International, Inc.
Predatory lending is rampant in low-income communities, draining over $2.4 billion from cash-strapped borrowers. Protect your finances and support responsible lending policies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results